What is ZYME's market cap?

$2.22B, based on the Nov 4 close of $30.94.

Does Zymeworks pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ZYME is sold short?

5.6M shares, 12.5% of float, as of Oct 15, 2026.

What sector is ZYME in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ZYMEHealthcarePharmaceuticals

Zymeworks Inc. (ZYME)

$30.94+2.69%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$30.94▲ 70.37% in range

Nov 4, 2025Low $16.46 · High $31.05Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Zymeworks closed at $30.94 on Nov 4, up 2.69%, 0.4% below its 52-week closing high. Volume of 1.0M shares was 0.72× its 20-day average (below normal).

Split-adjusted performance: +20.6% over one month, +12.1% over six months, +63.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $4.59M, down 90.6% from a year earlier, with a net margin of -980.8%.

Short interest was 5.6M shares at the Oct 15 settlement, up 5.4% from the prior report (12.5% of float, 4.4 days to cover).

Market cap$2.22B71.9M shares

Revenue · quarter$4.6M−90.6% YoY

Diluted EPS$-0.62−2166.7% YoY

P/E · TTM—P/S 59.9×

Net margin-980.8%Gross 100.0%

Dividend yieldNone

52-week range16.46 – 31.05−0.4% from high

Volume1.0M0.72× 20-day avg

Volatility · 60d47.0%Annualised

Short % of float12.5%4.4 days to cover

Net cash$270.7MCash $270.7M

Next earnings—Not scheduled

Split-adjusted performance

1W +7.1%1M +20.6%3M +33.8%6M +12.1%YTD +17.5%1Y +63.8%3Y +342.6%5Y +36.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum77

Revenue growth12

Net margin23

Value (low P/E)—

Size82

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short5.6M+5.4% vs prior

Days to cover4.4Settled Oct 15

% of float12.5%

Short vol. 10d51.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ZYMEZymeworks	$30.94	+2.69%	+12.1%	−90.6%	−980.8%	—	$2.22B
TRLVTrulieve Cannabis	$11.60	+0.52%	—	—	−149.8%	—	$2.23B	Compare
SEPNSepterna	$47.88	+9.57%	+93.8%	+22375.6%	−48.7%	—	$2.23B	Compare
PRGOPERRIGO	$15.83	+0.83%	+29.1%	−3.2%	7.3%	—	$2.20B	Compare
AUPHAurinia Pharmaceuticals	$17.11	+3.32%	+5.3%	+13.9%	37.9%	7.3	$2.29B	Compare
BHVNBiohaven	$15.24	−2.37%	+51.8%	—	—	—	$2.30B	Compare
IMNMImmunome	$19.52	−3.89%	−16.1%	−100.0%	—	—	$2.30B	Compare
VERAVera Therapeutics	$31.97	+4.10%	−12.6%	—	—	—	$2.30B	Compare
SDGRSchrodinger	$28.52	+4.93%	+119.7%	+7.5%	10.1%	—	$2.13B	Compare

News about Zymeworks

All news →

Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings GrowthZacks Investment Research · 6d ago▼ Negative Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026GlobeNewswire Inc. · Oct 24, 2026▲ Positive Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3GlobeNewswire Inc. · Oct 23, 2026▲ Positive Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsGlobeNewswire Inc. · Oct 15, 2026▲ Positive Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma AcquisitionGlobeNewswire Inc. · Sep 28, 2026▲ Positive

Quick answers

What does Zymeworks do?: Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates.
What is ZYME's market cap?: $2.22B, based on the Nov 4 close of $30.94.
Does Zymeworks pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ZYME is sold short?: 5.6M shares, 12.5% of float, as of Oct 15, 2026.
What sector is ZYME in?: Healthcare, in the Pharmaceuticals industry.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

HQ: Middletown, DE264 employeesListed Apr 28, 2017zymeworks.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology